Cover Image

Real-world characteristics of patients with severe asthma prior to starting dupilumab: the ProVENT study

Introduction: Dupilumab is approved for the treatment of severe type 2 (T2) asthma; however, the characteristics of patients receiving dupilumab in routine clinical practice are incompletely understood. This study describes the characteristics of patients with severe asthma before dupilumab treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Korn, Stephanie (Author) , Schmidt, Olaf (Author) , Timmermann, Hartmut (Author) , Watz, Henrik (Author) , Gappa, Monika (Author) , Radwan, Amr (Author) , De Prado Gomez, Lucia (Author) , Atenhan, Anne (Author) , Bărbuş, Sebastian Liviu (Author) , Thakur, Mayank (Author) , Lommatzsch, Marek (Author)
Format: Article (Journal)
Language:English
Published: January 2024
In: Respiration
Year: 2024, Volume: 103, Issue: 1, Pages: 10-21
ISSN:1423-0356
DOI:10.1159/000535390
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000535390
Verlag, lizenzpflichtig, Volltext: https://karger.com/res/article/103/1/10/871445/Real-World-Characteristics-of-Patients-with-Severe
Get full text
Author Notes:Stephanie Korn, Olaf Schmidt, Hartmut Timmermann, Henrik Watz, Monika Gappa, Amr Radwan, Lucia De Prado Gomez, Anne Atenhan, Sebastian Barbus, Mayank Thakur, Marek Lommatzsch
Description
Summary:Introduction: Dupilumab is approved for the treatment of severe type 2 (T2) asthma; however, the characteristics of patients receiving dupilumab in routine clinical practice are incompletely understood. This study describes the characteristics of patients with severe asthma before dupilumab treatment in a real-world setting. Methods: This interim analysis of an ongoing real-life study of dupilumab assessed baseline characteristics of the first patient cohort enrolled in the ProVENT study. Results: A total of 99 patients (59% females) were analyzed (17% received another biologic before dupilumab treatment and 15% were on maintenance oral corticosteroid treatment). Adult-onset asthma (>18 years) and an allergic phenotype were documented in 58% and 48% of patients, respectively. Median (interquartile range) age was 54 (40-61) years; the median number of exacerbations in the last 24 months was 1 (0-3); median fractional exhaled nitric oxide (FeNO) value was 38 (23-64) ppb; and median blood eosinophils (bEOS) count was 184 (8-505) cells/mu L. According to the United Kingdom Severe Asthma Registry classification, 53% of patients had T2 intermediate asthma (bEOS >= 150 cells/mu L or FeNO >= 25 ppb), 17% had T2 high asthma (bEOS >= 150 cells/mu L and FeNO >= 25 ppb), and 4% had T2 low asthma (bEOS <150 cells/mu L and FeNO <25 ppb). At least one GINA criterion for T2 airway inflammation was documented in 70% of patients. T2 comorbidities were observed in 64% of patients. Conclusions: This analysis suggests that patients eligible for dupilumab treatment display various clinical and biochemical characteristics rather than one clear-cut phenotype.
Item Description:Gesehen am 22.04.2024
Online verfügbar: 12 Dezember 2023
Physical Description:Online Resource
ISSN:1423-0356
DOI:10.1159/000535390

Similar Items